This Medical News article discusses recent efforts by the Department of Veterans Affairs to extend new hepatitis C treatments to all veterans within its health care system.
This Viewpoint describes how a shortage of health care workers providing treatment for hepatitis C hinders access to treatment, despite progress in drug efficacy and reductions in drug costs.
This Viewpoint describes clinical progress in eradicating hepatitis C virus infection, but emphasizes the importance of making treatment more cost-effective and accessible to all patients.
This randomized trial reports high rates of sustained virologic response in the first part of a open-label study of ombitasvir, paritaprevir (co-dosed with ritonavir), and dasabuvir with ribavirin for 63 patients with hepatitis C virus genotype 1 and human immunodeficiency virus 1 co-infection.
Kohli and coauthors review the safety, efficacy, and tolerability of current approved interferon-based regimens and oral interferon-free regimens for treating hepatitis C virus infection and provide treatment recommendations for specialists and generalists based on published evidence.
The PHOTON-1 investigators report that, after 12 or 24 weeks of treatment patients coinfected with HIV and hepatitis C virus who received an oral, interferon-free combination of sofosbuvir and ribavirin for 12 or 24 weeks had high rates of sustained virologic response.